The relationship between Helicobacter pylori infection and nonalcoholic fatty liver disease

doi:10.3877/cma.j.issn.1674-1358.2016.02.006

Abstract

Abstract:

Objective

To investigate the relationship between Helicobacter pylori (Hp) infection and nonalcoholic fatty liver disease (NAFLD).

Methods

The data from 3 447 cases who received ¹³C urea breath test to detect Hp and abdominal ultrasound examination from April to July 2014 in the physical examination center of the People’s Hospital of Shanxi Province were analyzed by cross-sectional analysis methods. The subjects were divided into NAFLD group and non-NAFLD group on the basis of abdominal ultrasound examination results, with 1 354 and 2 093 cases, respectively. The relationship between NAFLD prevalence rate and Hp infection status and the components of metabolic syndrome were analyzed by Unconditioned Logistic regression.

Results

In both cases, body mass index (BMI), triglycerides (TG) and uric acid (UA) levels were positive correlated with the prevalence rates of NAFLD. In the male subjects, low-density lipoprotein cholesterol (LDL-C), diastolic nlood pressure (DBP) and fasting plasma glucose (FPG) levels were positive correlated with NAFLD. In the female subjects, high-density lipoprotein cholesterol (HDL-C) level was negative correlated with NAFLD. There was no significant difference in the infection of Hp and level of total cholesterol (TC) in both gender.

Conclusions

There may be a connection between NAFLD prevalence rate and BMI, levels of TG, UA, LDL-C, HDL-C, FPG and DBP, but for infection rate of Hp and level of TC, there was no significant correlation.

Key words: Helicobacter pylori, Nonalcoholic fatty liver disease, Blood lipids, Fasting plasma glucose, Uric acid

Lu Wang, Na Fang, Yanqin Hao, Longfeng Zhao. The relationship between Helicobacter pylori infection and nonalcoholic fatty liver disease[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2016, 10(02): 157-161.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2016.02.006

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2016/V10/I02/157

Figures/Tables 3

References 29

[1]	Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori[J]. Clin Microbiol Rev,1997,10(4):720-741.
[2]	Suzuki H, Marshall BJ, Hibi T. Overview: Helicobacter pylori and extragastric disease[J]. Int J Hematol,2006,84(4):291-300.
[3]	中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年修订版)[J]. 中华肝脏病杂志,2010,18(3):163-166.
[4]	Takuma Y. Helicobacter pylori infection and liver diseases[J]. Gan To Kagaku Ryoho,2011,38(3):362-364.
[5]	Polyzos SA, Kountouras J, Papatheodorou A, et al. Helicobacter pylori infection in patients with non-alcoholic fatty liver disease[J]. Metabolism,2013,62(1):121-126.
[6]	彭朝阳，盛晓燕，丁海燕, 等. 幽门螺杆菌感染与非酒精性脂肪肝相关性研究[J]. 医学研究杂志,2014,43(6):153-156.
[7]	卢轶，沈哲，厉有名. 幽门螺杆菌感染和非酒精性脂肪性肝病的相关性分析:横断面研究[C]. 浙江: 浙江大学医学院附属第一医院,2013.
[8]	刘安楠，王蕾蕾，张晏, 等. 非酒精性脂肪性肝病与幽门螺杆菌感染的相关性[J]. 胃肠病学和肝病学杂志,2014,23(12):1451-04.
[9]	郭晓燕，史海涛，师阿盟, 等. 非酒精性脂肪性肝病患者幽门螺杆菌感染状况调查[J]. 实用肝脏病杂志,2013,16(5):451-453.
[10]	Okushin K, Takahashi Y, Yamamichi N, et al. Helicobacter pylori infection is not associated with fatty liver disease including non-alcoholic fatty liver disease: a large-scale cross-sectional study in Japan[J]. BMC Gastroenterology,2015,15(1):1-10.
[11]	李济宾，张晋昕. 代谢综合征的研究进展[J]. 中国健康教育,2010,26(7):528-532.
[12]	Reaven G. Why a cluster is truly a cluster: insulin resistance and cardiovascular disease[J]. Clin Chem,2008,54(5):785-787.
[13]	Kashyap SR, Defronzo RA. The insulin resistance syndrome: physiological considerations[J]. Diab Vasc Dis Res,2007;4(1):13-19.
[14]	Lu HM, Lei SD, Zhao JM, et al. Platelet activity in Chinese obese adolescents with and without insulin resistance[J]. J Theromb Thrombolys,2014,37(2):165-170.
[15]	Katagiri H, Yamada T, Oka Y. Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals[J]. Circ Res,2007,101(1):27-33.
[16]	Strazzullo P, Barbato A, Galletti F, et al. Abnormalities of renal sodium handling in the metabolic syndrome. results of the olivetti heart study[J]. J Hypertens,2006,24(8):1633-1639.
[17]	Pantelis A, Sarafidis MD, Anastasios N, et al. Insulin resisteance and endothelin: another pathway for renal injury in patients with the cardiometabolic syndrome?[J]. J Cardio Metabolic Syndrome,2008,3(3):183-187.
[18]	Penesova A, Vlcek M, Imrich R, et al. Hyperinsulinemia in newly diagnosed patients with multiple sclerosis[J]. J Metabolic Brain Disease,2015,30(4):895-901.
[19]	Gunji T, Matsuhashi N, Sato H, et al. Helicobacter pylori infection significantly increases insulin resistance in the asymptomatic Japanese population[J]. Helicobacter,2009,14(5):144-150.
[20]	Gunji T, Matsuhashi N, Sato H, et al. Helicobacter pylori infection is significantly associated with metabolic syndrome in the Japanese population[J]. Am J Gastroenterol,2008,103(12):3005-3010.
[21]	陆再英，钟南山，谢毅等主编. 内科学[M]. 7版. 北京: 人民卫生出版社,2011:800.
[22]	Cohen D, Muhsen K. Association between Helicobacter pylori colonization and glycated hemoglobin levels: is this another reason to eradicate H. pylori in adulthood?[J]. Infect Dis,2012,205(8):1183-1185.
[23]	Ioannou GN, Weiss NS, Kearney DJ. Is Helicobacter pylori seropositivity related to body mass index in the United States?[J].Aliment Pharmacol Ther,2005,21(6):765-772.
[24]	Cho I, Blaser MJ, François F, et al. Helicobacter pylori and overweight status in the United States: data from the Third National Health and Nutrition Examination Survey[J]. Am J Epidemiol,2005,162(6):579-584.
[25]	Wu MS, Lee WJ, Wang HH, et al. A case-control study of association of Helicobacter pylori infection with morbid obesity in Taiwan[J]. Arch Intern Med,2005,165(13):1552-1555.
[26]	Fujiwara Y, Higuchi K, Arafa UA, et al. Long-term effect of Helicobacter pylori eradication on quality of life, body mass index, and newly developed diseases in Japanese patients with peptic ulcer disease[J]. Hepatogastroenterology,2002,49(47):1298-1302.
[27]	Kamada T, Hata J, Kusunoki H, et al. Eradication of Helicobacter pylori increases the incidence of hyperlipidaemia and obesity in peptic ulcer patients[J]. Dig Liver Dis,2005,37:39-43.
[28]	Nwokolo CU, Freshwater DA, O’Hare P, et al. Plasma ghrelin following cure of Helicobacter pylori[J]. Gut,2003,52(5):637-640.
[29]	Konturek PC, Czenikiewicz-Guzik M, Bielanski W, et al. Involvement of Helicobacter pylori infection in neuro-hormonal control of food intake[J]. Physiol Pharmacol,2006,57(Suppl 5):S67-S81.

指标	非脂肪肝组（n = 2 093）	NAFLD组（n = 1 354）	统计量	P值
年龄（岁）	44（34，53）	47（39，54）	U =-5.495	0.000
性别（男/女）	927/1 166	1 018/336	χ² = 319.148	0.000
收缩压（mmHg）	118（108，129）	127（117，140）	U =-16.037	0.000
舒张压（mmHg）	74（68，80）	81（76，90）	U =-19.582	0.000
BMI（kg/m²）	23.20（21.34，25.08）	26.90（25.20，28.74）	U =-33.823	0.000
TG（mmol/L）	1.10（0.81，,1.53）	1.96（1.37，2.68）	U =-28.505	0.000
TC（mmol/L）	4.48（3.94，5.09）	4.78（4.21，5.40）	U =-8.778	0.000
HDL-C（mmol/L）	1.38（1.18，1.62）	1.13（0.97，1.34）	U =-21.008	0.000
LDL-C（mmol/L）	2.40（2.03，3.02）	2.80（2.10，3.32）	U =-9.478	0.000
FPG（mmol/L）	5.15（4.78，5.57）	5.51（5.04，6.11）	U =-14.489	0.000
UA（μmol/L）	276.38（233，334）	349.50（295.15，411.99）	U =-22.226	0.000
Hp（阳性/阴性）	992/1 101	713/641	χ² = 9.109	0.003

指标	非脂肪肝组（n = 2 093）	NAFLD组（n = 1 354）	统计量	P值
年龄（岁）	44（34，53）	47（39，54）	U =-5.495	0.000
性别（男/女）	927/1 166	1 018/336	χ² = 319.148	0.000
收缩压（mmHg）	118（108，129）	127（117，140）	U =-16.037	0.000
舒张压（mmHg）	74（68，80）	81（76，90）	U =-19.582	0.000
BMI（kg/m²）	23.20（21.34，25.08）	26.90（25.20，28.74）	U =-33.823	0.000
TG（mmol/L）	1.10（0.81，,1.53）	1.96（1.37，2.68）	U =-28.505	0.000
TC（mmol/L）	4.48（3.94，5.09）	4.78（4.21，5.40）	U =-8.778	0.000
HDL-C（mmol/L）	1.38（1.18，1.62）	1.13（0.97，1.34）	U =-21.008	0.000
LDL-C（mmol/L）	2.40（2.03，3.02）	2.80（2.10，3.32）	U =-9.478	0.000
FPG（mmol/L）	5.15（4.78，5.57）	5.51（5.04，6.11）	U =-14.489	0.000
UA（μmol/L）	276.38（233，334）	349.50（295.15，411.99）	U =-22.226	0.000
Hp（阳性/阴性）	992/1 101	713/641	χ² = 9.109	0.003

指标	Exp（B）	95%CI	P值
BMI	0.670	0.636～0.706	0.000
舒张压	0.976	0.961～0.990	0.001
TG	0.591	0.508～0.688	0.000
LDL-C	0.679	0.504～0.916	0.011
UA	0.996	0.995～0.998	0.000
FPG	0.835	0.768～0.908	0.000

指标	Exp（B）	95%CI	P值
BMI	0.670	0.636～0.706	0.000
舒张压	0.976	0.961～0.990	0.001
TG	0.591	0.508～0.688	0.000
LDL-C	0.679	0.504～0.916	0.011
UA	0.996	0.995～0.998	0.000
FPG	0.835	0.768～0.908	0.000

指标	Exp（B）	95%CI	P值
BMI	0.688	0.645～0.734	0.000
TG	0.691	0.544～0.878	0.002
LDL-C	3.822	1.927～7.581	0.000
血尿酸UA	0.994	0.992～0.997	0.000

Please choose a citation manager

Content to export